Dermatosparaxis Ehlers-Danlos syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1901OMIM:225410Q79.6
Who is this for?
Show terms as
7Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Dermatosparaxis Ehlers-Danlos syndrome (dEDS), formerly known as Ehlers-Danlos syndrome type VIIC, is an extremely rare heritable connective tissue disorder characterized by extreme skin fragility and laxity. The name 'dermatosparaxis' derives from Greek and Latin roots meaning 'tearing of skin.' This condition is caused by biallelic pathogenic variants in the ADAMTS2 gene, which encodes procollagen I N-proteinase, an enzyme essential for proper processing of type I procollagen into mature collagen fibrils. Without functional enzyme activity, collagen fibrils have an abnormal, hieroglyphic-like appearance on electron microscopy, leading to severely compromised connective tissue integrity. The condition primarily affects the skin, which is extremely fragile, soft, and doughy, with marked bruisability and sagging, redundant folds. Skin tears and wounds occur with minimal trauma, though wound healing is not typically severely impaired. Other characteristic features include large fontanelles and wide cranial sutures at birth, blue sclerae, micrognathia, short stature, joint hypermobility, umbilical or inguinal hernias, and premature rupture of fetal membranes. Affected individuals may also develop gingival hyperplasia and delayed closure of fontanelles. Unlike some other forms of Ehlers-Danlos syndrome, vascular complications and severe joint instability are generally less prominent, though careful monitoring is still warranted. There is currently no cure or specific disease-modifying therapy for dermatosparaxis EDS. Management is supportive and multidisciplinary, focusing on skin protection to minimize trauma, careful wound management, monitoring for hernias, and orthopedic surveillance for joint-related complications. Protective clothing and padding may help reduce skin injuries. Genetic counseling is recommended for affected families. Fewer than 30 cases have been reported in the medical literature worldwide, making this one of the rarest subtypes of Ehlers-Danlos syndrome.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormality of subcutaneous fat tissueHP:0001001Abnormal joint morphologyHP:0001367Hiatus herniaHP:0002036Coxa valgaHP:0002673RicketsHP:0002748OsteomalaciaHP:0002749Prolonged bleeding timeHP:0003010
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Dermatosparaxis Ehlers-Danlos syndrome.

View clinical trials →

No actively recruiting trials found for Dermatosparaxis Ehlers-Danlos syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Dermatosparaxis Ehlers-Danlos syndrome community →

Specialists

7 foundView all specialists →
FD
F S van Dijk
Specialist
1 Dermatosparaxis Ehlers-Danlos syndrome publication
PB
P Byers
Specialist
1 Dermatosparaxis Ehlers-Danlos syndrome publication
ED
E Dulfer
Specialist
1 Dermatosparaxis Ehlers-Danlos syndrome publication
JH
Juliette Harris
Specialist
1 Dermatosparaxis Ehlers-Danlos syndrome publication
IH
I Hausser
Specialist
1 Dermatosparaxis Ehlers-Danlos syndrome publication
AM
Abigail McElroy
LEAVENWORTH, KS
Specialist
1 Dermatosparaxis Ehlers-Danlos syndrome publication
GS
G Sobey
Specialist
1 Dermatosparaxis Ehlers-Danlos syndrome publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Dermatosparaxis Ehlers-Danlos syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Dermatosparaxis Ehlers-Danlos syndromeForum →

No community posts yet. Be the first to share your experience with Dermatosparaxis Ehlers-Danlos syndrome.

Start the conversation →

Latest news about Dermatosparaxis Ehlers-Danlos syndrome

No recent news articles for Dermatosparaxis Ehlers-Danlos syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Dermatosparaxis Ehlers-Danlos syndrome

What is Dermatosparaxis Ehlers-Danlos syndrome?

Dermatosparaxis Ehlers-Danlos syndrome (dEDS), formerly known as Ehlers-Danlos syndrome type VIIC, is an extremely rare heritable connective tissue disorder characterized by extreme skin fragility and laxity. The name 'dermatosparaxis' derives from Greek and Latin roots meaning 'tearing of skin.' This condition is caused by biallelic pathogenic variants in the ADAMTS2 gene, which encodes procollagen I N-proteinase, an enzyme essential for proper processing of type I procollagen into mature collagen fibrils. Without functional enzyme activity, collagen fibrils have an abnormal, hieroglyphic-lik

How is Dermatosparaxis Ehlers-Danlos syndrome inherited?

Dermatosparaxis Ehlers-Danlos syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Dermatosparaxis Ehlers-Danlos syndrome typically begin?

Typical onset of Dermatosparaxis Ehlers-Danlos syndrome is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Dermatosparaxis Ehlers-Danlos syndrome?

7 specialists and care centers treating Dermatosparaxis Ehlers-Danlos syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.